Efficacy and safety of homoharringtonine during consolidation therapy in chronic myeloid leukemia: a meta-analysis

doi:10.5246/jcps.2014.10.091

Abstract

Abstract:

本文旨在系统评价高三尖杉酯碱巩固治疗慢性粒细胞白血病的疗效和安全性。通过计算机检索PubMed、The Cochrane Library、EMbase、VIP、WanFang Data、CBM和CNKI 数据库, 检索时限均为从建库至2014年5月, 收集高三尖杉酯碱治疗慢性粒细胞白血病的随机对照试验。由两位研究者按照纳入与排除标准, 独立进行文献筛选、资料提取和评价纳入研究的方法学质量。采用RevMan 5.2软件进行Meta分析。结果共纳入5项研究, 423例患者。Meta分析结果显示: 高三尖杉酯碱组的完全血液学反应率、主要细胞遗传学反应率和部分细胞遗传学反应率高于羟基脲组, 完全细胞遗传学反应率和轻微细胞遗传学反应率均高于羟基脲组。高三尖杉酯碱组急变率低于羟基脲组, 4年预期生存率高于羟基脲组。高三尖杉酯碱的药物不良反应较轻。结果提示, 单用高三尖杉酯碱巩固治疗慢性粒细胞白血病具有较好的短期和远期疗效, 可作为部分患者的一个治疗选择。鉴于纳入研究的方法学质量存在中度选择性偏倚的可能性, 有待开展更多高质量大样本的随机双盲临床对照试验来验证。

Key words: 高三尖杉酯碱, 羟基脲, 慢性粒细胞白血病, Meta分析

CLC Number:

Supporting:

Huaiping Tian, Ping Yang, Rong Tao, Jinlian Zhang, Jian Zhang. Efficacy and safety of homoharringtonine during consolidation therapy in chronic myeloid leukemia: a meta-analysis[J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(10): 716-722.

References

[1] Sawyers, C.L. N. Engl. J. Med. 1999, 340, 1330-1340.

[2] Chinese Medical Association. Chin. J. Hematol. 2011, 32, 426-432.

[3] Druker, B.J.; Talpaz, M; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M. N. Engl. J. Med. 2001, 344, 1031-1037.

[4] Guilhot, F.; Apperley, J.; Kim, D.W.; Bullorsky, E.O.; Baccarani, M.; Roboz, G.J. Blood. 2007, 109, 4143-4150.

[5] Kantarjian, H.M.; Giles, F.; Quintás Cardama, A.; Cortes, J. Clin. Cancer Res.2007, 13, 1089-1097.

[6] Xu, B. Anti-tumor Pharmacy. 2013, 3, 162-165.

[7] Gandhi, V.; Plunkett, W.; Cortes, J.E. Clin. Cancer Res. 2014, 20, 1735-1740.

[8] O’Brien, S.; Kantarjian, H.; Koller, C.; Feldman, E.; Beran, M.; Andreeff, M. Blood. 1999, 93, 4149-4153.

[9] Chen, Y.; Li, S. Onco. Targets Ther. 2014, 31, 177-186.

[10] Kantarjian, H.M.; O’Brien, S.; Cortes, J. Clin. Lymphoma Myeloma Leuk. 2013, 13, 530-533.

[11] Moher, D.; Pham, B.; Jones, A.; Cook, D.J.; Jadad, A.R.; Moher, M.; Tugwell, P.; Klassen, T.P. Lancet. 1998, 352, 609-613.

[12] Higgins, J.P.T.; Grenn, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, updated March 2011.

[13] Zuo, A.L.; Mi, G.X. J. Leuk. Lymphoma. 2003, 12, 36-37.

[14] Li, Y.F.; Zhu, J.B.; Wang, C.L.; Ding, B.H.; Li, Y.Y; Xuan, H.B.; Qian, M.S. Chin. J. Cancer Res. 2005, 17, 150-l53.

[15] Shen, X.L.; Wei, W.; Zhang, B.Y.; Zhang, M.X.; Zhang, G.X.; Yang, J.B.; Liang, L. J. Changzhi Med. College. 2006, 20, 102-103.

[16] Wang, H.G. J. Med. Forum. 2007, 28, 70-71.

[17] Li, Y.F.; Deng, Z.K.; Xuan, H.B.; Zhu, J.B.; Ding, B.H.; Liu, X.N.; Chen, B.A. Chin. Med. J. 2009, 122, 1413-1417.

[18] Kantarijian, H.M.; Talpaz, M.; Santini, V.; Murgo, A.; Cheson, B.; O’Brien, S.M. Cancer.2001, 92, 1591-1605.

[19] O’brien, S.; Kantarjian, H.; Keating, M.; Beran, M.; Koller, C.; Robertson, L.E.; Hester, J.; Rios, M.B.; Andreeff, M.; Talpaz, M. Blood. 1995, 86, 3322-3326.

[20] Kurtin, S.E.; Matta, L. J. Adv. Pract. Oncol. 2013, 4, 257-262.

[21] Heiblig, M.; Sobh, M.; Nicolini, F.E. Leuk. Res. 2014, S0145-2126, 148-149.

[22] Narayanan, V.; Gutman, J.A.; Pollyea, D.A.; Jimeno, A. Drugs Today (Barc). 2013, 49, 447-456.

[23] Nazha, A.; Kantarjian, H.; Cortes, J.; Quintás-Cardama, A. Expert. Opin. Pharmacother. 2013, 14, 1977-1986.

[24] Kim, T.D.; Frick, M.; le Coutre, P. Expert. Opin. Pharmacother. 2011, 12, 2381-2392.

[25] Okabe, S.; Tauchi, T.; Tanaka, Y.; Katagiri, S.; Kitahara, T.; Ohyashiki, K. Blood. 2013, 122, 3086-3088.